Manana Elia

758 total citations
16 papers, 340 citations indexed

About

Manana Elia is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Manana Elia has authored 16 papers receiving a total of 340 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 10 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Manana Elia's work include Cancer Genomics and Diagnostics (7 papers), Breast Cancer Treatment Studies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Manana Elia is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Breast Cancer Treatment Studies (6 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Manana Elia collaborates with scholars based in United States, Belgium and Australia. Manana Elia's co-authors include Priyanka Sharma, Qamar J. Khan, Andrew K. Godwin, Jamie L. Wagner, Bruce F. Kimler, Shane R. Stecklein, Anne O’Dea, Roy A. Jensen, Jennifer R. Klemp and Marilee McGinness and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Manana Elia

16 papers receiving 338 citations

Peers

Manana Elia

ONCOL

PRM

GENET

Birgit Wackwitz Germany

Miklós Dióssy Denmark

Daniela Petriella Italy

Grazia Maria Vernaci Italy

Shreya Vemuri United States

Lingzhu Wen China

Lorian Menkema Netherlands

Vanesa Quiroga Spain

Kajsa Ericson Lindquist Sweden

Tommaso Giarratano Italy

Birgit Wackwitz Germany

Manana Elia

246 ×1.1

ONCOL

116 ×0.8

101 ×0.9

91 ×0.9

PRM

37 ×0.4

GENET

Citations per year, relative to Manana Elia Manana Elia (= 1×) peers Birgit Wackwitz

Countries citing papers authored by Manana Elia

Since Specialization

Citations

This map shows the geographic impact of Manana Elia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manana Elia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manana Elia more than expected).

Fields of papers citing papers by Manana Elia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manana Elia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manana Elia. The network helps show where Manana Elia may publish in the future.

Co-authorship network of co-authors of Manana Elia

This figure shows the co-authorship network connecting the top 25 collaborators of Manana Elia. A scholar is included among the top collaborators of Manana Elia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manana Elia. Manana Elia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Stecklein, Shane R., Bruce F. Kimler, Rachel Yoder, et al.. (2023). ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. npj Breast Cancer. 9(1). 10–10. 16 indexed citations

Stecklein, Shane R., Devin C. Koestler, Nanda Kumar Yellapu, et al.. (2023). Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).. Journal of Clinical Oncology. 41(16_suppl). 578–578. 3 indexed citations

Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2023). Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials. Cancer Research. 83(5_Supplement). PD11–7. 2 indexed citations

Stecklein, Shane R., Rachel Yoder, Roberto Salgado, et al.. (2023). Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy. Cancer Research. 83(5_Supplement). PD1–6. 2 indexed citations

Stecklein, Shane R., Rachel Yoder, Joshua M. Staley, et al.. (2023). Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.. Journal of Clinical Oncology. 41(16_suppl). 507–507. 4 indexed citations

Khan, Qamar J., Milind A. Phadnis, Manana Elia, et al.. (2023). Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.. Journal of Clinical Oncology. 41(16_suppl). 1007–1007. 7 indexed citations

Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2022). Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).. Journal of Clinical Oncology. 40(16_suppl). 513–513. 37 indexed citations

Sharma, Priyanka, Shane R. Stecklein, Bruce F. Kimler, et al.. (2022). Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease. Cancer Research. 82(4_Supplement). P2–1. 2 indexed citations

Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2021). Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). 1076–1076. 16 indexed citations

10.

Khan, Qamar J., Anne O’Dea, Aditya Bardia, et al.. (2020). Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).. Journal of Clinical Oncology. 38(15_suppl). 505–505. 47 indexed citations

11.

Sharma, Priyanka, Bruce F. Kimler, Anne O’Dea, et al.. (2019). Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).. Journal of Clinical Oncology. 37(15_suppl). 516–516. 7 indexed citations

12.

Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2018). Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1018–1018. 21 indexed citations

13.

Sharma, Priyanka, Jennifer R. Klemp, Bruce F. Kimler, et al.. (2014). Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Research and Treatment. 145(3). 707–714. 139 indexed citations

14.

Sharma, Priyanka, Jennifer R. Klemp, Bruce F. Kimler, et al.. (2013). Prospective evaluation of BRCA mutations in a large triple-negative breast cancer (TNBC) registry: Implications for germline testing.. Journal of Clinical Oncology. 31(15_suppl). 1026–1026. 1 indexed citations

15.

Howard, G.C.W., K. Clarke, Manana Elia, et al.. (1995). A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. British Journal of Cancer. 72(5). 1303–1306. 18 indexed citations

16.

Howard, G.C.W., K. Clarke, Manana Elia, et al.. (1995). A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. British Journal of Cancer. 72(5). 1307–1311. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact